<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04572854</url>
  </required_header>
  <id_info>
    <org_study_id>APL2-C3G-204</org_study_id>
    <nct_id>NCT04572854</nct_id>
  </id_info>
  <brief_title>Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN</brief_title>
  <acronym>NOBLE</acronym>
  <official_title>An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Apellis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Apellis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label, randomized, controlled study designed to evaluate&#xD;
      the safety and efficacy of pegcetacoplan in patients who have post-transplant recurrence of&#xD;
      C3G or IC-MPGN.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary efficacy endpoint is the proportion of patients with reduction in C3c staining on renal biopsy after 12 weeks of treatment with pegcetacoplan.</measure>
    <time_frame>12 weeks after enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number and incidence of treatment-related adverse events (AEs)</measure>
    <time_frame>52 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with reduction in C3c staining on renal biopsy</measure>
    <time_frame>52 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving at least a 50% reduction in proteinuria, over time</measure>
    <time_frame>52 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients achieving complete clinical remission of proteinuria, defined as normalization of proteinuria</measure>
    <time_frame>52 weeks after enrollment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of patients with stabilization or improvement in estimated glomerular filtration rate (eGFR), over time</measure>
    <time_frame>52 weeks after enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>C3G</condition>
  <condition>IC-MPGN</condition>
  <condition>Renal Transplant</condition>
  <condition>Complement 3 Glomerulopathy</condition>
  <condition>Complement 3 Glomerulopathy (C3G)</condition>
  <condition>Dense Deposit Disease</condition>
  <condition>Membranoproliferative Glomerulonephritis</condition>
  <condition>Membranoproliferative Glomerulonephritis (MPGN)</condition>
  <condition>Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pegcetacoplan treatment of 1080 mg (sub-cutaneous infusion) twice weekly will be given throughout the entire study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>No intervention given during the randomized controlled portion of the study (through week 12). After week 12, subjects will receive pegcetacoplan treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegcetacoplan</intervention_name>
    <description>Complement (C3) Inhibitor</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of at least 18 years of age at screening&#xD;
&#xD;
          -  Patients must have clinical and pathologic evidence of recurrent C3G or IC-MPGN, as&#xD;
             evidenced by all of the following:&#xD;
&#xD;
          -  Stable (not improving) or worsening disease, in the opinion of the investigator, in&#xD;
             the 2 months preceding the first dose of pegcetacoplan&#xD;
&#xD;
          -  eGFR ≥30 mL/min/1.73 m2, calculated by the Chronic Kidney Disease-Epidemiology&#xD;
             Collaboration (CKD-EPI) creatinine equation for adults&#xD;
&#xD;
          -  No more than 50% glomerulosclerosis or interstitial fibrosis on the screening renal&#xD;
             allograft biopsy&#xD;
&#xD;
          -  Stable regimen for recurrent C3G/IC-MPGN for at least 4 weeks prior to the screening&#xD;
             renal allograft biopsy and from the time of the screening renal allograft biopsy until&#xD;
             randomization&#xD;
&#xD;
          -  Willing to receive vaccinations against Neisseria meningitidis, Streptococcus&#xD;
             pneumoniae, and Haemophilus influenzae if applicable vaccination records are not&#xD;
             available&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous treatment with pegcetacoplan&#xD;
&#xD;
          -  Evidence of rejection on the screening renal allograft biopsy that requires treatment&#xD;
&#xD;
          -  Diagnosis or history of HIV, hepatitis B, or hepatitis C infection or positive&#xD;
             serology at screening indicative of infection&#xD;
&#xD;
          -  Malignancy, except for the following:&#xD;
&#xD;
          -  Cured basal or squamous cell skin cancer&#xD;
&#xD;
          -  Curatively treated in situ disease&#xD;
&#xD;
          -  Malignancy free and off treatment for ≥5 years&#xD;
&#xD;
          -  Significant renal disease in the renal allograft secondary to another condition (eg,&#xD;
             infection, malignancy, monoclonal gammopathy, rejection, or a medication) that would&#xD;
             confound interpretation of the study results&#xD;
&#xD;
          -  Participation in any other investigational drug trial or exposure to other&#xD;
             investigational agent, device, or procedure within 30 days or 5 half-lives from the&#xD;
             last dose of the investigational agent (whichever is longer) prior to screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Apellis Clinical Trial Information Line</last_name>
    <phone>+1 (617) 977-5700</phone>
    <email>clinicaltrials@apellis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Keck School of Medicine, University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>900033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Washington University, St.Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.theNOBLEstudy.com</url>
    <description>Study Website</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>April 7, 2021</last_update_submitted>
  <last_update_submitted_qc>April 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glomerulonephritis</mesh_term>
    <mesh_term>Glomerulonephritis, Membranoproliferative</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

